



ATTORNEY FILE NO. 20040117.ORI

SUPPLEMENTAL DECLARATION, POWER OF ATTORNEY, AND PETITION

As below named inventors, we hereby declare that: our residences, post office addresses and citizenships are as stated below next to our names; that we verily believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled "CONTROL OF GENE EXPRESSION USING A COMPLEX OF AN OLIGONUCLEOTIDE AND A REGULATORY PEPTIDE", the specification of which was filed on April 8, 2004, as application Serial No. 10/824,584.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to in the Oath or Declaration.

We acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s):

International Application No.: PCT/GB02/04633
International Filing Date: 11 October 2002
Priority Date Claimed: 11 October 2001
Entitled: CONTROL OF GENE EXPRESSION USING A COMPLEX
OF AN OLIGONUCLEOTIDE AND A REGULATORY
PEPTIDE

We hereby appoint NIKOLAI & MERSEREAU, P.A., (Customer Number 23595), a professional association, consisting of the following attorneys/agents and the following attorneys/agents individually: Thomas J. Nikolai, Registration No. 19,283; Charles G. Mersereau, Registration No. 26,205; and Steven E. Kahm, Registration No. 30,860 of 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone No. (612) 339-7461, our attorneys/agents with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all phone calls and correspondence to: C. G. Mersereau, Esq. at NIKOLAI & MERSEREAU, P.A., 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone: (612) 339-7461.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: _____
Stephen Hart

Name: _____
Simak Ali

Date: _____

Date: _____

Residence:
London, W12 0NN, UK

Residence:
London, W12 0NN, UK

Citizenship:
British

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom


Name: Boris Tumi PuFong

Date: _____

Residence:
London, NW1 0TU, UK

Citizenship:
British

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Name: 
Laki Buluwela

Date: 19/6/04

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: Andrew C. G. Porter

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Gene Targeting Group
MRC Clinical Sciences Centre
Hammersmith Hospital
Du Cane Road
Hammersmith Campus
London W12 0NN
United Kingdom

Name: _____
Satu Vainikka

Date: _____

Residence:
London, NW1 0TU, UK

Citizenship:
Finish

Post Office Address:
Gene Expression Tehcnologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Name: _____
John David Jenkinson

Name: _____
Patrick Kanda

Date: _____

Date: _____

Residence:
London, NW1 0TU, UK

Residence:
London, NW1 0TU, UK

Citizenship:
British

Citizenship:
United States of America

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom



ATTORNEY FILE NO. 20040117.ORI

SUPPLEMENTAL DECLARATION, POWER OF ATTORNEY, AND PETITION

As below named inventors, we hereby declare that: our residences, post office addresses and citizenships are as stated below next to our names; that we verily believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled "CONTROL OF GENE EXPRESSION USING A COMPLEX OF AN OLIGONUCLEOTIDE AND A REGULATORY PEPTIDE", the specification of which was filed on April 8, 2004, as application Serial No. 10/824,584.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to in the Oath or Declaration.

We acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s):

International Application No.: PCT/GB02/04633
International Filing Date: 11 October 2002
Priority Date Claimed: 11 October 2001
Entitled: CONTROL OF GENE EXPRESSION USING A COMPLEX
OF AN OLIGONUCLEOTIDE AND A REGULATORY
PEPTIDE

We hereby appoint NIKOLAI & MERSEREAU, P.A., (Customer Number 23595), a professional association, consisting of the following attorneys/agents and the following attorneys/agents individually: Thomas J. Nikolai, Registration No. 19,283; Charles G. Mersereau, Registration No. 26,205; and Steven E. Kahm, Registration No. 30,860 of 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone No. (612) 339-7461, our attorneys/agents with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all phone calls and correspondence to: C. G. Mersereau, Esq. at NIKOLAI & MERSEREAU, P.A., 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone: (612) 339-7461.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name:

Stephen Hart

Date:

23/6/04

Residence:

London, W12 0NN, UK

Citizenship:

British

Post Office Address:

Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name:

Simak Ali

Date:

19/6/04

Residence:

London, W12 0NN, UK

Citizenship:

British

Post Office Address:

Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: Boris Tumi PuFong

Date: _____

Residence:
London, NW1 0TU, UK

Citizenship:
British

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Name: Laki Buluwela

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: Andrew C. G. Porter

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Gene Targeting Group
MRC Clinical Sciences Centre
Hammersmith Hospital
Du Cane Road
Hammersmith Campus
London W12 0NN
United Kingdom

Name: Satu Vainikka

Date: 3/6/04

Residence:
London, ~~NW1 0TU~~, UK

Citizenship:
Finish

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Name: D.J.S. -
John David Jenkinson

Date: 14/06/04

Residence:
London, NW1 OTU, UK

Citizenship:
British

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 OTU
United Kingdom

Name: Patrick Kanda
Patrick Kanda

Date: 07/06/2004

Residence:
London, NW1 OTU, UK

Citizenship:
United States of America

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 OTU
United Kingdom



ATTORNEY FILE NO. 20040117.ORI

SUPPLEMENTAL DECLARATION, POWER OF ATTORNEY, AND PETITION

As below named inventors, we hereby declare that: our residences, post office addresses and citizenships are as stated below next to our names; that we verily believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled "CONTROL OF GENE EXPRESSION USING A COMPLEX OF AN OLIGONUCLEOTIDE AND A REGULATORY PEPTIDE", the specification of which was filed on April 8, 2004, as application Serial No. 10/824,584.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to in the Oath or Declaration.

We acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s):

International Application No.: PCT/GB02/04633
International Filing Date: 11 October 2002
Priority Date Claimed: 11 October 2001
Entitled: CONTROL OF GENE EXPRESSION USING A COMPLEX
OF AN OLIGONUCLEOTIDE AND A REGULATORY
PEPTIDE

We hereby appoint NIKOLAI & MERSEREAU, P.A., (Customer Number 23595), a professional association, consisting of the following attorneys/agents and the following attorneys/agents individually: Thomas J. Nikolai, Registration No. 19,283; Charles G. Mersereau, Registration No. 26,205; and Steven E. Kahm, Registration No. 30,860 of 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone No. (612) 339-7461, our attorneys/agents with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all phone calls and correspondence to: C. G. Mersereau, Esq. at NIKOLAI & MERSEREAU, P.A., 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone: (612) 339-7461.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: _____
Stephen Hart

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: _____
Simak Ali

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: Boris Tumi PuFong

Date: _____

Residence:
London, NW1 0TU, UK

Citizenship:
British

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Name: Andrew C. G. Porter

Date: 18/6/04

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Gene Targeting Group
MRC Clinical Sciences Centre
Hammersmith Hospital
Du Cane Road
Hammersmith Campus
London W12 0NN
United Kingdom

Name: Laki Buluwela

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: Satu Vainikka

Date: _____

Residence:
London, NW1 0TU, UK

Citizenship:
Finish

Post Office Address:
Gene Expression Tehcnologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Name: John David Jenkinson

Name: Patrick Kanda

Date: _____

Date: _____

Residence:
London, NW1 0TU, UK


Residence:
London, NW1 0TU, UK

Citizenship:
British

Citizenship:
United States of America

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 0TU
United Kingdom



ATTORNEY FILE NO. 20040117.ORI

DECLARATION, POWER OF ATTORNEY, AND PETITION

As below named inventors, we hereby declare that: our residences, post office addresses and citizenships are as stated below next to our names; that we verily believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled "CONTROL OF GENE EXPRESSION USING A COMPLEX OF AN OLIGONUCLEOTIDE AND A REGULATORY PEPTIDE", the specification of which was filed on April 8, 2004, as application Serial No. 10/824,584.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to in the Oath or Declaration.

We acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s):

International Application No.: PCT/GB02/04633
International Filing Date: 11 October 2002
Priority Date Claimed: 11 October 2001
Entitled: CONTROL OF GENE EXPRESSION USING A COMPLEX
OF AN OLIGONUCLEOTIDE AND A REGULATORY
PEPTIDE

We hereby appoint NIKOLAI & MERSEREAU, P.A., (Customer Number 23595), a professional association, consisting of the following attorneys/agents and the following attorneys/agents individually: Thomas J. Nikolai, Registration No. 19,283; Charles G. Mersereau, Registration No. 26,205; and Steven E. Kahm, Registration No. 30,860 of 820 International Centre, 900 Second Avenue South,

Minneapolis, Minnesota 55402-3813; Telephone No. (612) 339-7461, our attorneys/agents with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all phone calls and correspondence to: C. G. Mersereau, Esq. at NIKOLAI & MERSEREAU, P.A., 820 International Centre, 900 Second Avenue South, Minneapolis, Minnesota 55402-3813; Telephone: (612) 339-7461.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: _____
Stephen Hart

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: _____
Simak Ali

Date: _____

Residence:
London, W12 0NN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 0NN
United Kingdom

Name: *PuFong*
Boris Tumi PuFong

Date: 6th December 2005

Residence:
London, NW1 OTU, UK

Citizenship:
British

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London HA2 6DE
United Kingdom
47 PARKSIDE WAY
NORTH HARROW
HA2 6DE
MIDDLESEX, UNITED KINGDOM

Name: Laki Buluwela

Date: _____

Residence:
London, W12 ONN, UK

Citizenship:
British

Post Office Address:
Division of Medicine
Cancer Cell Biology Section
Imperial College School of
Medicine
Hammersmith Campus
Room 601b Cyclotron Building
Du Cane Road
London W12 ONN
United Kingdom

Name: _____
Andrew C. G. Porter

Date: _____

Residence:
London, W12 ONN, UK

Citizenship:
British

Post Office Address:
Gene Targeting Group
MRC Clinical Sciences Centre
Hammersmith Hospital
Du Cane Road
Hammersmith Campus
London W12 ONN
United Kingdom

Name: _____
Satu Vainikka

Date: _____

Residence:
London, NW1 OTU, UK

Citizenship:
Finish

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 OTU
United Kingdom

Name: John David Jenkinson

Date: _____

Residence:
London, NW1 OTU, UK

Citizenship:
British

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 OTU
United Kingdom

Name: Patrick Kanda

Date: _____

Residence:
London, NW1 OTU, UK

Citizenship:
United States of America

Post Office Address:
Gene Expression Technologies
The London BioScience
Innovation Centre
Royal College Street
London NW1 OTU
United Kingdom